Jupiter Neurosciences, Inc. Common Stock (JUNS) - Net Assets
Based on the latest financial reports, Jupiter Neurosciences, Inc. Common Stock (JUNS) has net assets worth $57.42K USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.58 Million) and total liabilities ($2.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read Jupiter Neurosciences, Inc. Common Stock (JUNS) financial obligations for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $57.42K |
| % of Total Assets | 2.23% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Jupiter Neurosciences, Inc. Common Stock - Net Assets Trend (2019–2024)
This chart illustrates how Jupiter Neurosciences, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Jupiter Neurosciences, Inc. Common Stock assets under control for the complete picture of this company's asset base.
Annual Net Assets for Jupiter Neurosciences, Inc. Common Stock (2019–2024)
The table below shows the annual net assets of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2024. For live valuation and market cap data, see Jupiter Neurosciences, Inc. Common Stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $4.17 Million | +171.91% |
| 2023-12-31 | $-5.80 Million | +18.80% |
| 2022-12-31 | $-7.14 Million | -37.98% |
| 2021-12-31 | $-5.18 Million | -39.52% |
| 2020-12-31 | $-3.71 Million | +26.02% |
| 2019-12-31 | $-5.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Jupiter Neurosciences, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1803585200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $3.31K | 0.08% |
| Other Components | $30.19 Million | 723.65% |
| Total Equity | $4.17 Million | 100.00% |
Jupiter Neurosciences, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Jupiter Neurosciences, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
NextEye Co. Ltd
KQ:137940
|
$13.43 Million |
|
TJGC Group Limited
NASDAQ:TJGC
|
$13.43 Million |
|
Nuvotec
KQ:060260
|
$13.44 Million |
|
NETUM GROUP OYJ
F:79J
|
$13.44 Million |
|
Skycorp Solar Group Limited Ordinary Shares
NASDAQ:PN
|
$13.42 Million |
|
Turk Ilac ve Serum Sanayi AS
IS:TRILC
|
$13.41 Million |
|
Inepar S.A. Indústria e Construções
SA:INEP3
|
$13.40 Million |
|
Sarama Resource
V:SWA
|
$13.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jupiter Neurosciences, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -5,801,352 to 4,172,008, a change of 9,973,360.
- Net loss of 2,439,625 reduced equity.
- New share issuances of 9,875,213 increased equity.
- Other factors increased equity by 2,537,772.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.44 Million | -58.48% |
| Share Issuances | $9.88 Million | +236.7% |
| Other Changes | $2.54 Million | +60.83% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Jupiter Neurosciences, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.69x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.57 | $0.39 | x |
| 2020-12-31 | $-0.42 | $0.39 | x |
| 2021-12-31 | $-0.55 | $0.39 | x |
| 2022-12-31 | $-0.22 | $0.39 | x |
| 2023-12-31 | $-0.18 | $0.39 | x |
| 2024-12-31 | $0.14 | $0.39 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jupiter Neurosciences, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -58.48%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.49x
- Recent ROE (-58.48%) is below the historical average (-9.75%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.55 Million |
| 2020 | 0.00% | -146.92% | 2.05x | 0.00x | $-1.28 Million |
| 2021 | 0.00% | -686.39% | 0.96x | 0.00x | $-3.86 Million |
| 2022 | 0.00% | -2125.15% | 0.99x | 0.00x | $-4.24 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.20 Million |
| 2024 | -58.48% | 0.00% | 0.00x | 1.49x | $-2.86 Million |
Industry Comparison
This section compares Jupiter Neurosciences, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jupiter Neurosciences, Inc. Common Stock (JUNS) | $57.42K | 0.00% | 43.87x | $13.43 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phas… Read more